{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:13:36Z","timestamp":1792242816591,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18fk0108015"],"award-info":[{"award-number":["JP18fk0108015"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although more than 10\u2009years have passed since HPV vaccination was implemented, first as an interim programme (Emergent vaccine promotion programme) in November 2010, followed by incorporating into the National Immunization Programme in April, 2013 and suspended in June 2013, limited studies have investigated the HPV vaccine effectiveness against high-grade cervical lesions in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We collected the matched data of the results of cervical biopsy and history of vaccination from the Japan Cancer Society database. The subjects were women aged 20 to 29\u2009years screened for cervical cancer between April, 2015 and March, 2017, and with information on HPV vaccination status. We estimated the relative risk of developing high-grade cervical lesions in vaccinated subjects using Poisson regression as compared to unvaccinated subjects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 34,281 women screened, 3770 (11.0%) were vaccinated. The prevalence of CIN2+ was statistically\u00a0significantly lower in the vaccinated women as compared to the unvaccinated women (Vaccine Effectiveness (VE) =76%; RR\u2009=\u20090.24, 95% CI:0.10\u20130.60). High VE against CIN3+ was also observed (91%; RR\u2009=\u20090.09, 95% CI:0.00\u20130.42).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Women aged 20\u201329\u2009years who received at least one dose of HPV vaccine had a significantly lower risk of high-grade cervical lesions than those not vaccinated. In Japan, HPV vaccination should be resumed in order to reduce the incidence of cervical cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-020-05513-6","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T05:02:58Z","timestamp":1604552578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women"],"prefix":"10.1186","volume":"20","author":[{"given":"Yuki","family":"Shiko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9403-1339","authenticated-orcid":false,"given":"Ryo","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Sauvaget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Kakizoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"issue":"8","key":"5513_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pi\u00f1eros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941\u201353. \n                  https:\/\/doi.org\/10.1002\/ijc.31937\n                  \n                .","journal-title":"Int J Cancer"},{"key":"5513_CR2","unstructured":"Comprehensive Survey of Living Conditions. \n                  https:\/\/www.e-stat.go.jp\/stat-search\/files?page=1&layout=datalist&toukei=00450061&tstat=000001141126&cycle=7&tcl..ass1=000001141142&tclass2=000001142127&stat_infid=000031964454\n                  \n                . Accessed 8 Oct 2020 (in Japanese)."},{"issue":"1","key":"5513_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(sici)1096-9896(199909)189:1%3C12::aid-path431%3E3.0.co;2-f","volume":"189","author":"JM Walboomers","year":"1999","unstructured":"Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12\u20139. \n                  https:\/\/doi.org\/10.1002\/(sici)1096-9896(199909)189:1%3C12::aid-path431%3E3.0.co;2-f\n                  \n                .","journal-title":"J Pathol"},{"issue":"1","key":"5513_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1046\/j.1525-1381.1999.99723.x","volume":"5","author":"H zur Hausen","year":"1987","unstructured":"zur Hausen H. Papillomaviruses in human cancer. Appl Pathol. 1987;5(1):19\u201324. \n                  https:\/\/doi.org\/10.1046\/j.1525-1381.1999.99723.x\n                  \n                .","journal-title":"Appl Pathol"},{"issue":"19","key":"5513_CR5","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1056\/nejmoa061741","volume":"356","author":"FUTURE II Study Group","year":"2007","unstructured":"FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915\u201327. \n                  https:\/\/doi.org\/10.1056\/nejmoa061741\n                  \n                .","journal-title":"N Engl J Med"},{"issue":"10108","key":"5513_CR6","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1016\/s0140-6736(17)31821-4","volume":"390","author":"WK Huh","year":"2017","unstructured":"Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16\u201326 years: a randomised, double-blind trial. Lancet (London, England). 2017;390(10108):2143\u201359. \n                  https:\/\/doi.org\/10.1016\/s0140-6736(17)31821-4\n                  \n                .","journal-title":"Lancet (London, England)"},{"issue":"9679","key":"5513_CR7","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/s0140-6736(09)60691-7","volume":"373","author":"N Munoz","year":"2009","unstructured":"Munoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24\u201345 years: a randomised, double-blind trial. Lancet (London, England). 2009;373(9679):1949\u201357. \n                  https:\/\/doi.org\/10.1016\/s0140-6736(09)60691-7\n                  \n                .","journal-title":"Lancet (London, England)"},{"issue":"9686","key":"5513_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/s0140-6736(09)61248-4","volume":"374","author":"J Paavonen","year":"2009","unstructured":"Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet (London, England). 2009;374(9686):301\u201314. \n                  https:\/\/doi.org\/10.1016\/s0140-6736(09)61248-4\n                  \n                .","journal-title":"Lancet (London, England)"},{"key":"5513_CR9","unstructured":"Immunization, Vaccines and Biologicals. World Health Organization. \n                  https:\/\/www.who.int\/immunization\/monitoring_surveillance\/en\/\n                  \n                . Accessed 8 Oct 2020."},{"key":"5513_CR10","doi-asserted-by":"publisher","unstructured":"Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagu\u00e9 X, et al. Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89\u201399. \n                  https:\/\/doi.org\/10.1016\/S1470-2045(11)70286-8\n                  \n                .","DOI":"10.1016\/S1470-2045(11)70286-8"},{"issue":"12","key":"5513_CR11","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/cid\/ciw647","volume":"63","author":"K Tsuda","year":"2016","unstructured":"Tsuda K, Yamamoto K, Leppold C, Tanimoto T, Kusumi E, Komatsu T, et al. Trends of media coverage on human papillomavirus vaccination in Japanese newspapers. Clin Infect Dis. 2016;63(12):1634\u20138. \n                  https:\/\/doi.org\/10.1093\/cid\/ciw647\n                  \n                .","journal-title":"Clin Infect Dis"},{"key":"5513_CR12","unstructured":"Ministry of Health Labour and Welfare and Demographic and Health Statistics. Division. Municipalities survey 2014. Tokyo. \n                  http:\/\/www.mhlw.go.jp\/topics\/bcg\/other\/5.html\n                  \n                . Accessed 8 Oct 2020."},{"key":"5513_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pvr.2018.02.002","volume":"5","author":"S Suzuki","year":"2018","unstructured":"Suzuki S, Hosono A. No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: results of the Nagoya study. Papillomavirus Res. 2018;5:96\u2013103. \n                  https:\/\/doi.org\/10.1016\/j.pvr.2018.02.002\n                  \n                .","journal-title":"Papillomavirus Res"},{"issue":"3","key":"5513_CR14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/s1470-2045(18)30836-2","volume":"20","author":"KT Simms","year":"2019","unstructured":"Simms KT, Steinberg J, Caruana M, Smith MA, Lew JB, Soerjomataram I, et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. Lancet Oncol. 2019;20(3):394\u2013407. \n                  https:\/\/doi.org\/10.1016\/s1470-2045(18)30836-2\n                  \n                .","journal-title":"Lancet Oncol"},{"issue":"5","key":"5513_CR15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.5694\/mja15.01038","volume":"204","author":"JM Brotherton","year":"2016","unstructured":"Brotherton JM, Gertig DM, May C, Chappell G, Saville M. HPV vaccine impact in Australian women: ready for an HPV-based screening program. Med J Aust. 2016;204(5):184\u2013e1. \n                  https:\/\/doi.org\/10.5694\/mja15.01038\n                  \n                .","journal-title":"Med J Aust"},{"issue":"12","key":"5513_CR16","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1002\/ijc.30035","volume":"138","author":"E Herweijer","year":"2016","unstructured":"Herweijer E, Sundstrom K, Ploner A, Uhnoo I, Sparen P, Arnheim-Dahlstrom L. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: a population-based study. Int J Cancer. 2016;138(12):2867\u201374. \n                  https:\/\/doi.org\/10.1002\/ijc.30035\n                  \n                .","journal-title":"Int J Cancer"},{"issue":"3","key":"5513_CR17","doi-asserted-by":"publisher","first-page":"e20151968","DOI":"10.1542\/peds.2015-1968","volume":"137","author":"LE Markowitz","year":"2016","unstructured":"Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137(3):e20151968. \n                  https:\/\/doi.org\/10.1542\/peds.2015-1968\n                  \n                .","journal-title":"Pediatrics."},{"issue":"1","key":"5513_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.vaccine.2013.10.085","volume":"32","author":"D Mesher","year":"2013","unstructured":"Mesher D, Soldan K, Howell-Jones R, Panwar K, Manyenga P, Jit M, et al. Reduction in HPV 16\/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine. 2013;32(1):26\u201332. \n                  https:\/\/doi.org\/10.1016\/j.vaccine.2013.10.085\n                  \n                .","journal-title":"Vaccine."},{"issue":"9","key":"5513_CR19","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1038\/bjc.2014.479","volume":"111","author":"KG Pollock","year":"2014","unstructured":"Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer. 2014;111(9):1824\u201330. \n                  https:\/\/doi.org\/10.1038\/bjc.2014.479\n                  \n                .","journal-title":"Br J Cancer"},{"issue":"10","key":"5513_CR20","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S1473-3099(14)70841-2","volume":"14","author":"SN Tabrizi","year":"2014","unstructured":"Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014;14(10):958\u201366. \n                  https:\/\/doi.org\/10.1016\/S1473-3099(14)70841-2\n                  \n                .","journal-title":"Lancet Infect Dis"},{"key":"5513_CR21","doi-asserted-by":"publisher","first-page":"l1161","DOI":"10.1136\/bmj.l1161","volume":"365","author":"T Palmer","year":"2019","unstructured":"Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ. 2019;365:l1161. \n                  https:\/\/doi.org\/10.1136\/bmj.l1161\n                  \n                .","journal-title":"BMJ."},{"issue":"2","key":"5513_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1620\/tjem.240.147","volume":"240","author":"N Ozawa","year":"2016","unstructured":"Ozawa N, Ito K, Tase T, Metoki H, Yaegashi N. Beneficial effects of human papillomavirus vaccine for prevention of cervical abnormalities in Miyagi. Japan Tohoku J Exp Med. 2016;240(2):147\u201351. \n                  https:\/\/doi.org\/10.1620\/tjem.240.147\n                  \n                .","journal-title":"Japan Tohoku J Exp Med"},{"issue":"10","key":"5513_CR23","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/jog.13419","volume":"43","author":"H Tanaka","year":"2017","unstructured":"Tanaka H, Shirasawa H, Shimizu D, Sato N, Ooyama N, Takahashi O, et al. Preventive effect of human papillomavirus vaccination on the development of uterine cervical lesions in young Japanese women. J Obstet Gynaecol Res. 2017;43(10):1597\u2013601. \n                  https:\/\/doi.org\/10.1111\/jog.13419\n                  \n                .","journal-title":"J Obstet Gynaecol Res"},{"issue":"52","key":"5513_CR24","doi-asserted-by":"publisher","first-page":"7913","DOI":"10.1016\/j.vaccine.2018.05.048","volume":"36","author":"R Konno","year":"2018","unstructured":"Konno R, Konishi H, Sauvaget C, Ohashi Y, Kakizoe T. Effectiveness of HPV vaccination against high-grade cervical lesions in Japan. Vaccine. 2018;36(52):7913\u20135. \n                  https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.048\n                  \n                .","journal-title":"Vaccine."},{"key":"5513_CR25","volume-title":"WHO Classification of Tumours of Female Reproductive Organs, 4th ed.: IARC","author":"RJ Kurman","year":"2014","unstructured":"Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Organs, 4th ed.: IARC; 2014."},{"key":"5513_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.pvr.2015.05.005","volume":"1","author":"JML Brotherton","year":"2015","unstructured":"Brotherton JML, Malloy M, Budd AC, Saville M, Drennan KT, Gertig DM. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: observational cohort of young women in Australia. Papillomavirus Res. 2015;1:59\u201373. \n                  https:\/\/doi.org\/10.1016\/j.pvr.2015.05.005\n                  \n                .","journal-title":"Papillomavirus Res."},{"key":"5513_CR27","doi-asserted-by":"publisher","first-page":"g1458","DOI":"10.1136\/bmj.g1458","volume":"348","author":"E Crowe","year":"2014","unstructured":"Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348:g1458. \n                  https:\/\/doi.org\/10.1136\/bmj.g1458\n                  \n                .","journal-title":"BMJ."},{"key":"5513_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.pvr.2019.01.004","volume":"7","author":"P Basu","year":"2019","unstructured":"Basu P, Muwonge R, Bhatla N, Nene BM, Joshi S, Esmy PO, et al. Two-dose recommendation for human papillomavirus vaccine can be extended up to 18 years - updated evidence from Indian follow-up cohort study. Papillomavirus Res. 2019;7:75\u201381. \n                  https:\/\/doi.org\/10.1016\/j.pvr.2019.01.004\n                  \n                .","journal-title":"Papillomavirus Res."},{"key":"5513_CR29","unstructured":"WHO Position Paper on Vaccines against Human Papillomavirus (HPV). \n                  https:\/\/www.who.int\/immunization\/policy\/position_papers\/hpv\/en\/\n                  \n                . Accessed 8 Oct 2020."},{"key":"5513_CR30","doi-asserted-by":"publisher","first-page":"100177","DOI":"10.1016\/j.pvr.2019.100177","volume":"8","author":"JM Brotherton","year":"2019","unstructured":"Brotherton JM, Budd A, Rompotis C, Bartlett N, Malloy MJ, Andersen RL, et al. Is one dose of human papillomavirus vaccine as effective as three?: a national cohort analysis. Papillomavirus Res. 2019;8:100177. \n                  https:\/\/doi.org\/10.1016\/j.pvr.2019.100177\n                  \n                .","journal-title":"Papillomavirus Res."},{"key":"5513_CR31","doi-asserted-by":"publisher","unstructured":"Verdoodt F, Dehlendorff C, Kjaer SK. Dose-related effectiveness of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia: a Danish nationwide cohort study. Clin Infect Dis. 2019. \n                  https:\/\/doi.org\/10.1093\/cid\/ciz239\n                  \n                .","DOI":"10.1093\/cid\/ciz239"},{"issue":"7","key":"5513_CR32","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/s1470-2045(16)30121-8","volume":"17","author":"C Sauvaget","year":"2016","unstructured":"Sauvaget C, Nishino Y, Konno R, Tase T, Morimoto T, Hisamichi S. Challenges in breast and cervical cancer control in Japan. Lancet Oncol. 2016;17(7):e305\u2013e12. \n                  https:\/\/doi.org\/10.1016\/s1470-2045(16)30121-8\n                  \n                .","journal-title":"Lancet Oncol"},{"key":"5513_CR33","unstructured":"Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan. \n                  http:\/\/gdb.ganjoho.jp\/graph_db\/gdb1\n                  \n                . Accessed 8 Oct 2020 (in Japanese)."},{"issue":"10135","key":"5513_CR34","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/s0140-6736(18)30854-7","volume":"391","author":"B Corcoran","year":"2018","unstructured":"Corcoran B, Clarke A, Barrett T. Rapid response to HPV vaccination crisis in Ireland. Lancet (London, England). 2018;391(10135):2103. \n                  https:\/\/doi.org\/10.1016\/s0140-6736(18)30854-7\n                  \n                .","journal-title":"Lancet (London, England)"},{"key":"5513_CR35","unstructured":"WHO Director-General calls for all countries to take action to help end the suffering caused by cervical cancer. \n                  https:\/\/www.who.int\/reproductivehealth\/call-to-action-elimination-cervical-cancer\/en\/\n                  \n                . Accessed 8 Oct 2020."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05513-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-05513-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05513-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T21:02:59Z","timestamp":1604696579000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05513-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5513"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05513-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.13649\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.13649\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.13649\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,5]]},"assertion":[{"value":"15 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The appropriate research ethics committee granted an exemption of the requirement for ethics review, and deemed that informed consent was not required because the analysis used anonymized records from a pre-existing database.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RK reports his personal lecture fee from Chugai Pharmaceuticals, Japan Vaccine Co Ltd., MSD, Mochida Co Ltd., Roche Diagnostics and BD, and grant for his institute from Chugai Pharmaceuticals, outside the submitted work. He is the Director of the Executive Board Members of the Japanese Expert Board for the Eradication of Cervical Cancer, which has received funding from Qiagen, MSD, Chugai Pharmaceuticals and GlaxoSmithKline, outside the submitted work. Those personal fees and funding have no influence on the manuscript. YO reports personal fees from Statcom, personal fees from Sanofi, grants and personal fees from Eisai, personal fees from Chugai, personal fees from Taiho, personal fees from Shionogi, personal fees from Kowa, non-financial support from Yakult Honsha, non-financial support from Takeda, personal fees from Public Health Research Foundation, personal fees from Daiicchi-Sankyo, outside the submitted work. Those personal fees and funding have no influence on the manuscript. SY, HK, CS and TK declare no competing of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"808"}}